Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May:4:100094.
doi: 10.1016/j.lanepe.2021.100094. Epub 2021 Apr 13.

Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide

Karl Kunzelmann  1
Affiliations

Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide

Karl Kunzelmann. Lancet Reg Health Eur. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

KK has nothing to declare and no competing interests. Patent application by the University of Regensburg, 93053 Regensburg, Germany. PCT/EP2019/077433: COMPOUND FOR USE IN THE TREATMENT OF A DISEASE CHARACTERIZED BY DYSREGULATED MUCUS PRODUCTION AND/OR SECRETION.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Backer V., Sjöbring U., Sonne J., Weiss A., Hostrup M., Johansen H.K., et al. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide - a broad spectrum antiviral candidate for treatment of COVID-19 the lancet regional health - Europe (in press). 2021. DOI: https://doi.org/10.1016/j.lanepe.2021.100084 - PMC - PubMed
    1. Jurgeit A., McDowell R., Moese S., Meldrum E., Schwendener R., Greber U.F. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10) - PMC - PubMed
    1. Miner K., Labitzke K., Liu B., Elliot R., Wang P., Henckels K. Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol. 2019;14:51. 10. - PMC - PubMed
    1. Kunzelmann K., Ousingsawat J., Cabrita I., Doušová T., Bähr A., Janda M. TMEM16A in cystic fibrosis: activating or inhibiting? Front Pharmacol. 2019;29:3. 10. - PMC - PubMed
    1. Cabrita I., Benedetto R., Schreiber R., Kunzelmann K. Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight. 2019;8 - PMC - PubMed

LinkOut - more resources